Sangamo Therapeutics (SGMOQ) Receivables - Net (2010 - 2025)

Sangamo Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $371000.0 for Q4 2025.

• On a quarterly basis, Receivables - Net fell 25.8% year-over-year to $371000.0 in Q4 2025; TTM through Dec 2025 was $371000.0, a 25.8% decrease from a year earlier, with the FY2025 full-year figure at $371000.0, down 25.8% from the prior year.
• Receivables - Net slipped to $371000.0 in Q4 2025 per SGMOQ's latest filing, from $523000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $10.5 million in Q3 2024 and bottomed at $366000.0 in Q1 2025.
• The 5-year median for Receivables - Net is $3.2 million (2022), against an average of $3.7 million.
• Across the five-year window, Receivables - Net jumped 814.29% in 2024 and plunged 95.02% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $6.0 million in 2021, then sank by 38.47% to $3.7 million in 2022, then plunged by 75.05% to $923000.0 in 2023, then tumbled by 45.83% to $500000.0 in 2024, then slipped by 25.8% to $371000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Receivables - Net figures stand at $371000.0 (Q4 2025), $523000.0 (Q3 2025), and $372000.0 (Q2 2025).